IL2 and melanoma: Fibromun has now progressed to phase III clinical trials, including a study in combination with doxorubicin for patients with metastatic soft-tissue sarcoma (EudraCT number 2016–003239-38) (68), and another in combination with L19-IL2 (Darleukin) for patients with fully resectable stage IIIB/C melanoma (ClinicalTrials.gov identifier NCT02938299; EudraCT number 2015–002549-72) (69).